Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025 ...

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

Novo Nordisk decodes India’s obesity drug market with Wegovy positioned as once-a-week novel weight management medication: ...

Danish pharma giant Novo Nordisk’s announcement comes months after the launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.

Novo Nordisk launches Wegovy® in India, a weight management therapy reducing cardiovascular risks for people with obesity.

Novo Nordisk launches weightloss drug Wegovy in India at competitive prices, facing patent battles and high demand.